Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Charles River Laboratories International EV-to-EBITDA?
Charles River Laboratories InternationalCRL -0.14%70 EV-to-EBITDA is 46.39 as of Jul. 22, 2026, which is 183% above its 10-year median of 16.40. GuruFocus rates CRL with a GF Score™ of 70/100 and a GF Value™ of $194.01 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Charles River Laboratories International ranks worse than 90.6% on this metric.
CRL's EV-to-EBITDA is ranked worse than 90.6% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.48
vs CRL: 46.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Charles River Laboratories International (NYSE:CRL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Charles River Laboratories International's PE Ratio (TTM) for today is calculated as:
Charles River Laboratories International's share price for today is $219.40.
Charles River Laboratories International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International EV-to-EBITDA Chart
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's EV-to-EBITDA falls into.
Charles River Laboratories International's current Enterprise Value is $13,480 Mil.
Charles River Laboratories International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $291 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (CRL) has a EV-to-EBITDA of 46.39 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Charles River Laboratories International. This is 183% above median its historical median of 16.40. Over the past decade, Charles River Laboratories International's EV-to-EBITDA has ranged from 10.94 to 49.34. According to the industry distribution chart, Charles River Laboratories International ranks #106 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 90.6%.
Is Charles River Laboratories International's EV-to-EBITDA too high?
Charles River Laboratories International's current EV-to-EBITDA of 46.39 is 183% above median its 10-year median of 16.40. Over the past 10 years, this metric has ranged from a low of 10.94 to a high of 49.34. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.48. Charles River Laboratories International's value of 46.39 is 220.4% above this industry median. Based on the distribution chart, Charles River Laboratories International ranks #106 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's EV-to-EBITDA compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #106 out of 117 companies for EV-to-EBITDA. This places Charles River Laboratories International in the lower half of its industry. The industry median EV-to-EBITDA is 14.48. Charles River Laboratories International's value of 46.39 is 220.4% above this benchmark. Historically, Charles River Laboratories International's own EV-to-EBITDA has ranged from 10.94 to 49.34 over the past decade. While the company's 10-year median is 16.40 vs. the industry median of 14.48, Charles River Laboratories International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.48, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current EV-to-EBITDA of 46.39 is 220.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Charles River Laboratories International. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current EV-to-EBITDA is 46.39, which is 183% above median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.01, compared to a current price of $219.40 — trading 13.1% above its estimated fair value. The current EV-to-EBITDA is 46.39, which is 183% above median its 10-year median of 16.40 and 220.4% above the Medical Diagnostics & Research industry median of 14.48. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current EV-to-EBITDA is 46.39 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $219.40 is trading 13.1% above its estimated GF Value™ of $194.01.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for CRL:
EV-to-EBITDA: 46.39 (183% above median its 10-year median of 16.40)
GF Value™: $194.01 vs. price of $219.40 (13.1% above fair value)
Industry Position: 220.4% above the Medical Diagnostics & Research median (#106 of 117)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for CRL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
